As part of its monetary and financial policy measures to further mitigate the impact of the coronavirus pandemic on households, and businesses, the Central Bank of Nigeria (CBN), has approved regulatory forbearance for the restructuring of credit facilities in the Other Financial Institution (OFI) sub-sector.
This was disclosed in a circular signed by the CBN’s Director for Financial Policy and Regulatory Department, Kevin Amugo, on Wednesday, May 27, 2020.
In the circular, stated that Amugo the apex bank will be reducing interest rates on its facilities through participating financial institutions from 9% to 5% per annum for a year with effect from March 1, 2020.
According to the circular, CBN has approved regulatory forbearance for the restructuring of credit facilities in the OFI sub-sector as follows:
‘’CBN Intervention facilities availed through participating OFIs are granted a further one-year moratorium on all principal repayments, effective March 1, 2020.
‘’Interest rates on the CBN intervention facilities through participating OFIs hereby reduced from 9% to 5% per annum for 1-year effective March 1, 2020.
‘’OFIs are granted leave to consider temporary and time-limited restructuring of the tenor and loan terms for households and businesses affected by COVID-19, subject to the recently issued guidelines for restructuring affected credit facilities in the OFIs sub-sector.”
This new policy measure by the apex bank is in continuation of its intervention in the nation’s economy so as to help manage the crisis caused by the coronavirus pandemic and reduce its effects on household and businesses.
This is coming a day before the Monetary Policy Committee (MPC) meeting for the month of May which has been slated for tomorrow Thursday, May 27, 2020.
Meanwhile, the CBN said that it shall continue to monitor developments and implement appropriate measures to safeguard financial stability and support stakeholders impacted by the COVID-19 pandemic.
COVID-19: Moderna says it will produce 500 million vaccines by 2021
Moderna Inc, has said that the company has the capacity to produce up to 500 million coronavirus vaccines by 2021.
Stéphane Bancel, CEO of pharmaceutical company and Covid-19 vaccine maker, Moderna Inc, has said that the company has the capacity to produce up to 500 million coronavirus vaccines by 2021.
The CEO disclosed this at the Nasdaq Investor Conference, as reported by Reuters.
What you should know
- Nairametrics reported last month that the pharmaceutical company had stated that its Covid-19 vaccine was 94.5% effective in treating coronavirus, after preliminary analysis of a large late-stage clinical trial.
- UK Health Secretary, Matt Hancock announced in November that the UK had secured 5 million doses of the vaccine.
The company disclosed that they had applied for emergency use of the vaccine in the United States and EU after finalizing clinical trials which showed 94.1% efficacy, and would hold a December 17 meeting with the American Food and Drug Administration to discuss emergency use.
“For 500 million, I am very comfortable we are gonna get there (2021),” Bancel said at the Nasdaq Investor Conference.
The CEO added that the price for its vaccine would remain at $37 per dose, but expected it to fall to $25 as purchase volumes rose.
Moderna says up to 125 million doses of its Covid-19 vaccine will be supplied globally by the first quarter of 2021.
COVID-19 Update in Nigeria
On the 4th of December 2020, 324 new confirmed cases were recorded in Nigeria
The spread of novel Corona Virus Disease (COVID-19) in Nigeria continues to record significant increases as the latest statistics provided by the Nigeria Centre for Disease Control reveal Nigeria now has 68,627 confirmed cases.
On the 4th of December 2020, 324 new confirmed cases were recorded in Nigeria, having carried out a total daily test of 7,101 samples across the country.
To date, 68,627 cases have been confirmed, 64,467 cases have been discharged and 1,179 deaths have been recorded in 36 states and the Federal Capital Territory. A total of 791,539 tests have been carried out as of December 4th, 2020 compared to 779,708 tests a day earlier.
COVID-19 Case Updates- 4th December 2020,
- Total Number of Cases – 68,627
- Total Number Discharged – 64,467
- Total Deaths – 1,179
- Total Tests Carried out – 791,539
According to the NCDC, the 324 new cases were reported from 11 states- Lagos (115), FCT (110), Kaduna (57), Taraba (9), Akwa Ibom (8), Plateau (6), Bauchi (4), Ekiti (4), Kano(4), Katsina (4) and Rivers (3).
Meanwhile, the latest numbers bring Lagos state total confirmed cases to 23,660, followed by Abuja (7,101), Plateau (3,910), Oyo (3,730), Kaduna (3,302), Rivers (3,009), Edo (2,705), Ogun (2,237), Delta (1,824), Kano (1,803), Ondo (1,728), Enugu (1,332), Kwara (1,110), Ebonyi (1,055), Katsina (1,034), Osun (947), Gombe (938). Abia (926), Bauchi (782), and Borno (745).
Imo State has recorded 681 cases, Nasarawa (507), Benue (496), Bayelsa (456), Ekiti (381), Akwa Ibom (348), Jigawa (331), Niger (298), Anambra (285), Adamawa (261), Taraba (172), Sokoto (166), Yobe (100), Kebbi (93), Cross River (90), Zamfara (79), while Kogi state has recorded 5 cases only.
Lock Down and Curfew
In a move to combat the spread of the pandemic disease, President Muhammadu Buhari directed the cessation of all movements in Lagos and the FCT for an initial period of 14 days, which took effect from 11 pm on Monday, 30th March 2020.
The movement restriction, which was extended by another two weeks period, has been partially put on hold with some businesses commencing operations from May 4. On April 27th, 2020, Nigeria’s President, Muhammadu Buhari declared an overnight curfew from 8 pm to 6 am across the country, as part of new measures to contain the spread of the COVID-19. This comes along with the phased and gradual easing of lockdown measures in FCT, Lagos, and Ogun States, which took effect from Saturday, 2nd May 2020, at 9 am.
On Monday, 29th June 2020 the federal government extended the second phase of the eased lockdown by 4 weeks and approved interstate movement outside curfew hours with effect from July 1, 2020. Also, on Monday 27th July 2020, the federal government extended the second phase of eased lockdown by an additional one week.
On Thursday, 6th August 2020 the federal government through the secretary to the Government of the Federation (SGF) and Chairman of the Presidential Task Force (PTF) on COVID-19 announced the extension of the second phase of eased lockdown by another four (4) weeks.
Covid-19: WHO says the promise of vaccine is a game changer
The WHO has stated that the promise of Covid-19 vaccines is phenomenal and potentially game-changing.
The World Health Organization has said that the promise of Covid-19 vaccines is phenomenal and potentially game-changing.
This disclosure was made by the WHO’s Regional Director for Europe, Hans Kluge, during a press briefing at Copenhagen on Thursday, December 2, 2020, according to a report from Reuters.
Kluge said there are expectations that there would be limited supplies of Covid-19 vaccine supplies at the early stages and as such countries must decide who gets priority.
However, the WHO emphasized that there is a growing consensus among stakeholders that older people, medical workers, and people that share the virus with some other health conditions will be among the first recipients of the vaccine.
What you should know
It can be recalled that yesterday, UK regulator gave its approval to the Covid-19 vaccine, which was developed by Pfizer Inc in collaboration with BioNTech, moving ahead of the rest of the world, including the United States in the race to begin the most crucial mass inoculation programme in history.
- This follows the announcement by Pfizer that the vaccine proved 95% effective in a final analysis of clinical-trial data for its phase 3 study.
- In addition, Biotech firm, Moderna Inc, also announced that its Covid-19 experimental vaccine was 94.5% effective in a preliminary study.
- The United States and European Union regulators are sifting through the same Pfizer vaccine trial data, but are yet to give their approval.
- The WHO revealed on Wednesday it had received data from Pfizer and BioNTech on the vaccine and was reviewing it for possible listing for emergency use, a minimum condition for countries to authorize national use.